TITLE

HER-2 and Herceptin

AUTHOR(S)
Cartagena, Ana
PUB. DATE
August 2005
SOURCE
CMAJ: Canadian Medical Association Journal;8/16/2005, Vol. 173 Issue 4, p348
SOURCE TYPE
Academic Journal
DOC. TYPE
Question & Answer
ABSTRACT
Provides answers to questions concerning human epidermal growth factor receptor 2 (HER-2) and Herceptin. Role of HER-2 in regulating cell growth; Effect of Herceptin on HER-2 receptors; Number of ongoing clinical trials of Herceptin in 2005.
ACCESSION #
17857785

 

Related Articles

  • Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Tovey, S. M.; Brown, S.; Doughty, J. C.; Mallon, E. A.; Cooke, T. G.; Edwards, J. // British Journal of Cancer;3/10/2009, Vol. 100 Issue 5, p680 

    We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant...

  • Clinical: Journals Watch - Dermatitis, obesity and vaccines.  // GP: General Practitioner;11/4/2005, p46 

    This article presents information on some recent articles on research related to dermatitis, obesity and vaccines. One of the articles titled "Childhood Obesity and Socioeconomic Group" presents a study which indicates that the prevalence of obesity rose from over 1 percent in 1974 to over 6...

  • Inconsistency of HER2 Test Raises Questions. Tuma, Rabiya S. // JNCI: Journal of the National Cancer Institute;7/18/2007, Vol. 99 Issue 14, p1064 

    The article discusses the problem regarding the inconsistency of tests used in identifying breast cancer patients whose tumors express the human epidermal growth factor receptor 2 (HER2)/neu protein. One research indicates that some patients who have tested negative for HER2 on both tests still...

  • HER2 Therapy � An Abundance of Riches. Gradishar, William J. // New England Journal of Medicine;1/12/2012, Vol. 366 Issue 2, p176 

    The article discusses the results of the Clinical Evaluation of Pertuzumab and Trastuzumab clinical trial. This randomized trial in patients focused on the use of first-line therapy with trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive breast...

  • Precision medicine and personalized breast cancer: combination pertuzumab therapy. Reynolds, Kerry; Sarangi, Sasmit; Bardia, Aditya; Dizon, Don S. // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p95 

    Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for antibody-based targeted therapy in breast cancer. Pertuzumab, another humanized monoclonal antibody, binds to a different domain of HER2 and prevents the...

  • Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Sawaki, Masataka // Breast Cancer: Targets & Therapy;2014, Vol. 6, p37 

    Abstract: Anti-HER2 agents, such as trastuzumab, lapatinib, trastuzumab emtansine (T-DM1), and pertuzumab, are standard agents in the treatment of breast cancer overexpressing the human epidermal growth factor receptor 2 (HER2). Trastuzumab is the first approved HER2-targeted agent. Subsequent...

  • Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Olson, E. M.; Lin, N. U.; DiPiro, P. J.; Najita, J. S.; Krop, I. E.; Winer, E. P.; Burstein, H. J. // Annals of Oncology;Jan2012, Vol. 23 Issue 1, p93 

    Background: Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following treatment with trastuzumab-MCC-DM1...

  • HER2 standards could be unsuitable in determining trastuzumab use in breast cancer patients. Burress, Paul // Hem/Onc Today;3/25/2008, Vol. 9 Issue 5, p27 

    This article reports that the present standards for HER2 protein determination may not be ideal for choosing which breast cancer patients receive adjuvant trastuzumab. The results from the National Surgical Adjuvant Breast and Bowel Project B-31 clinical trial, which examined the addition of...

  • Trastuzumab beyond progression: a cost-utility analysis. Matter-Walstra, K. W.; Dedes, K. J.; Schwenkglenks, M.; Brauchli, P.; Szucs, T. D.; Pestalozzi, B. C. // Annals of Oncology;Nov2010, Vol. 21 Issue 11, p2161 

    Background: The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity.Patients and methods: A Markov cohort...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics